Literature DB >> 30008874

Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA.

Ke Xiao1, Zhengxiao Ouyang2, Hui-Huan Tang3.   

Abstract

The aim of the present study was to investigate whether the proliferation and metastasis of hilar cholangiocarcinoma cells can be suppressed and whether apoptosis can be induced by small interfering RNA (siRNA) repression of vascular endothelial growth factor (VEGF). siRNA sequences targeting the VEGF gene were designed and the human hilar cholangiocarcinoma QBC939, HCCC-9810 and RBE cell lines were transfected with VEGF-siRNA plasmids for 48 h. Reverse transcription-quantitative polymerase chain reaction and western blotting measured the levels of VEGF-A, VEGF-C and matrix metalloproteinase 2 (MMP2) mRNA expression and protein content. The cell invasion potential was evaluated using the Transwell invasion and migration assay and the MTT assay was employed to detect the proliferation of hilar cholangiocarcinoma cells. Flow cytometry was used to quantify cell apoptosis and necrosis. Following the transfection of VEGF-siRNA, a significant reduction of mRNA and protein levels of VEGF-A, VEGF-C and MMP2 was observed in the hilar cholangiocarcinoma cells. The invasion, migration and proliferation of tumor cells were also notably decreased. The rate of tumor cell apoptosis was increased in the VEGF-siRNA group (15.42%) compared with the non-siRNA control (2.22%) and the negative control (2.71%) groups. It was concluded that blocking the expression of VEGF via VEGF-siRNA effectively inhibited the invasion, migration and proliferation, and induced apoptosis in hilar cholangiocarcinoma cells. These observations suggested that targeting VEGF with RNAi may be an effective therapeutic strategy for treating hilar cholangiocarcinoma.

Entities:  

Keywords:  apoptosis; hilar cholangiocarcinoma; metastasis; proliferation; small interfering RNA; vascular endothelial growth factor

Year:  2018        PMID: 30008874      PMCID: PMC6036491          DOI: 10.3892/ol.2018.8840

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  An increasing incidence of cholangiocarcinoma: why?

Authors:  Laurie Blendis; Zamir Halpern
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

Review 3.  [RNA interference (RNAi) and its therapeutic potential in cancer].

Authors:  Salvador Vázquez-Vega; Adriana Contreras-Paredes; Marcela Lizano-Soberón; Alfredo Amador-Molina; Alejandro García-Carrancá; Lilia Patricia Sánchez-Suárez; Luis Benítez-Bribiesca
Journal:  Rev Invest Clin       Date:  2010 Jan-Feb       Impact factor: 1.451

4.  Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases.

Authors:  Suvendu Das; Daniel S Ladell; Simona Podgrabinska; Vladimir Ponomarev; Chandandeep Nagi; John T Fallon; Mihaela Skobe
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

5.  Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer.

Authors:  Jing Chen; Hua Wu; Deyan Han; Changsheng Xie
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

6.  Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.

Authors:  Alicia Beeghly-Fadiel; Xiao-Ou Shu; Wei Lu; Jirong Long; Qiuyin Cai; Yong-Bing Xiang; Ying Zheng; Zhongming Zhao; Kai Gu; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-11-30       Impact factor: 4.254

7.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

Review 8.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

Review 9.  Hilar cholangiocarcinoma: current management.

Authors:  Fumito Ito; Clifford S Cho; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

Review 10.  The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma.

Authors:  Manish A Shah
Journal:  Clin Adv Hematol Oncol       Date:  2014-04
View more
  4 in total

1.  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.

Authors:  Qiaohong Wang; Jingze Gao; Wen Di; Xia Wu
Journal:  Cancer Immunol Immunother       Date:  2020-04-28       Impact factor: 6.968

Review 2.  The role of tumour microenvironment: a new vision for cholangiocarcinoma.

Authors:  Ziyan Chen; Pengyi Guo; Xiaozai Xie; Haitao Yu; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

3.  Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model.

Authors:  Changcan Li; Bao Jin; Hang Sun; Yunchao Wang; Haitao Zhao; Xinting Sang; Huayu Yang; Yilei Mao
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

4.  27-Hydroxycholesterol-induced EndMT acts via STAT3 signaling to promote breast cancer cell migration by altering the tumor microenvironment.

Authors:  Kailin Jiao; Jing Zhen; Maoxuan Wu; Mengying Teng; Keke Yang; Qian Zhou; Chunyan Hu; Ming Zhou; Yuan Li; Zhong Li
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.